Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction

Lung cancer represents the leading cause of cancer-related death in developed countries. Despite the advances in diagnostic and therapeutic techniques, the 5-year survival rate remains low. The research for novel therapies directed to biological targets has modified the therapeutic approach, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortunato, O, Boeri, M, Moro, M, Verri, C, Mensah, M, Conte, D, Caleca, L, Roz, L, Pastorino, U, Sozzi, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454158/
https://www.ncbi.nlm.nih.gov/pubmed/25501825
http://dx.doi.org/10.1038/cddis.2014.507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454158/
https://www.ncbi.nlm.nih.gov/pubmed/25501825
http://dx.doi.org/10.1038/cddis.2014.507

Ejemplares similares